Opinion

Video

Evaluating 3L Treatment Landscape Evolution

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Related Videos
Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.
Related Content
Organ Preservation Decisions in Rectal Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 27th 2025

Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

CRC | Image Credit: © Anatomy Insider – stock.adobe.com
January 27th 2025

Fruquintinib Plus TAS-102 Demonstrates Efficacy and Acceptable Toxicity in Pretreated mCRC

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Gastrointestinal Cancer | Image Credit: © Crystal light – stock.adobe.com
January 27th 2025

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

CRC | © Sebastian Kaulitzki – stock.adobe.com
January 26th 2025

Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC